OSTX stock news · OS Therapies
Get alerts for OSTX
Follow OS Therapies (OSTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OSTXOS Therapies has started the process to get approval for Herlystic in the U.K. to help prevent cancer from coming back.
Good for OSTXOS Therapies began a U.K. application process for Herlystic and expects to finish in Q4 2026. This is a favorable step, but the treatment has not been approved.
OS Therapies Inc has signed an important agreement to offer new warrants at a lower price.
Bad for OSTXOS Therapies received about $7.2 million in gross cash, but issued shares and new warrants for an equal number. The extra shares that could follow make this unfavorable for current owners.
OS Therapies says its bone cancer treatment helped 72.7% of patients survive for three years.
Good for OSTXOS Therapies reported a significant survival advantage for OST-HER2, supporting its prospects. The comparison used historical patients, and early-access filings are still planned, not approved.
OS Therapies Inc has made a big agreement and named Frank Knuettel II as CFO and Kerry Clem as CCO.
NeutralOS Therapies named a new finance chief and commercial chief. The finance chief has relevant experience, but no deal or business result was announced, so the outlook is unchanged.
OS Therapies Inc shares details about selling up to 5,874,094 of its own stock.
Bad for OSTXOS Therapies filed to allow resale of 5,874,094 shares by selling stockholders; this increases available supply and reads as bearish for OSTX.
OS Therapies Inc announces the establishment of a significant definitive agreement (OSTX).
Good for OSTXOS Therapies Inc has filed a Form 8-K indicating its entry into a material definitive agreement, which is likely to have immediate implications for its business strategy and investor sentiment.